AMPH Overview

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The Company manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.

Wall Street analysts forecast AMPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMPH is32.00 USD with a low forecast of 30.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Amphastar Pharmaceuticals Inc revenue for the last quarter amounts to 183.10M USD, decreased -1.83

Amphastar Pharmaceuticals Inc. EPS for the last quarter amounts to 0.52 USD, decreased -29.73

Amphastar Pharmaceuticals Inc (AMPH) has 1976 emplpoyees as of March 22 2026.

Today AMPH has the market capitalization of 884.72M USD.